Characterizing outcomes of biliary tract cancers BTC with β-catenin CTNNB1 alterations | Caris Life Sciences
Home / Research / Publications / Characterizing outcomes of biliary tract cancers BTC with β-catenin CTNNB1 alterations

Publications

Characterizing outcomes of biliary tract cancers BTC with β-catenin CTNNB1 alterations

Background

  • Aberrant Wnt/β-catenin activation has been implicated in tumor formation, progression in BTC.
  • CTNNB1 is a key transcriptional co-activator in canonical Wnt signaling.
  • The impact of CTNNB1 alterations on outcomes in intrahepatic (IHCC) vs extrahepatic (EHCC) vs gallbladder (GB) tumors and patterns of gene co-expression is unclear.
  • We examined the molecular correlates and predictive and prognostic significance of CTNNB1 alterations in a real-world cohort of patients (pts) with BTC.
Download Publication
Learn More
Name(Required)